ESTRO 2024 - Abstract Book

S2420

Clinical - Urology

ESTRO 2024

in all the analyzed domains, whereas those in the higher SBRT dose group (40 Gy) experienced a gradual reduction in the QoL that was only mildly significant (>0.5σ) for the bowel and irritative/obstructive urinary aspects at 24 months (figure 2).

Figure 1

Figure 2

Conclusion:

In localized prostate cancer, mpMRI-guided risk adapted dose intensification SBRT is associated with an excellent morphological and functional response control and a safe toxicity profile.

Keywords: SBRT, prostate cancer, QoL